GSA Capital Partners LLP Grows Stock Position in Invivyd, Inc. $IVVD

GSA Capital Partners LLP boosted its position in Invivyd, Inc. (NASDAQ:IVVD) by 85.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 805,221 shares of the company’s stock after buying an additional 369,891 shares during the period. GSA Capital Partners LLP’s holdings in Invivyd were worth $886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after acquiring an additional 1,834,970 shares during the period. AQR Capital Management LLC increased its stake in shares of Invivyd by 2,051.0% during the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after acquiring an additional 391,617 shares during the period. Marshall Wace LLP purchased a new position in Invivyd during the second quarter worth about $158,000. Jane Street Group LLC acquired a new stake in Invivyd in the second quarter valued at about $147,000. Finally, Invesco Ltd. boosted its holdings in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Invivyd

In other Invivyd news, insider Robert D. Allen III sold 19,392 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $30,639.36. Following the sale, the insider owned 114,487 shares of the company’s stock, valued at $180,889.46. This represents a 14.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Julie Green sold 20,964 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the sale, the insider directly owned 107,717 shares in the company, valued at approximately $170,192.86. The trade was a 16.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 227,172 shares of company stock worth $354,534. Insiders own 25.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on IVVD shares. HC Wainwright boosted their target price on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Finally, Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.55 on Friday. The stock has a fifty day moving average price of $2.16 and a 200 day moving average price of $1.76. The stock has a market cap of $361.34 million, a PE ratio of -3.30 and a beta of 0.60. Invivyd, Inc. has a 1 year low of $0.46 and a 1 year high of $3.07.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.